{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T22:32:35Z","timestamp":1787005955265,"version":"build-2736575974"},"reference-count":38,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2007,3,1]],"date-time":"2007-03-01T00:00:00Z","timestamp":1172707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aust N Z J Psychiatry"],"published-print":{"date-parts":[[2007,3]]},"abstract":"<jats:p>Objective: To (i) test whether atomoxetine is non-inferior to methylphenidate in treating symptoms of attention deficit hyperactivity disorder (ADHD) in paediatric patients; and (ii) determine the tolerability of the two drugs.<\/jats:p>\n                  <jats:p>\n                    Method: This double-blind study was conducted in 6- to 16-year-old outpatients with ADHD (DSM-IV) in China, Korea and Mexico (January\u2013October 2004). Patients were randomly assigned to once-daily atomoxetine (0.8\u20131.8 mg kg\n                    <jats:sup>\u22121<\/jats:sup>\n                    day\n                    <jats:sup>\u22121<\/jats:sup>\n                    ; n = 164) or twice-daily methylphenidate (0.2\u20130.6 mg kg\n                    <jats:sup>\u22121<\/jats:sup>\n                    day\n                    <jats:sup>\u22121<\/jats:sup>\n                    ; n = 166) for \u223c8 weeks. Primary efficacy assessment was the comparison of response rates (\u226540% reduction from baseline to end point in total score) on the Attention Deficit Hyperactivity Disorder Rating Scale-IV-Parent Version: Investigator-Administered and -Scored. Tolerability measures included, but were not limited to, the assessment of treatment-emergent adverse events (TEAEs) and weight.\n                  <\/jats:p>\n                  <jats:p>Results: Atomoxetine was non-inferior to methylphenidate in improving ADHD symptoms based on response rates (atomoxetine, 77.4%; methylphenidate, 81.5%; one-sided 95% lower confidence limit = \u221211.7%, p = 0.404). Treatment-emergent adverse effects experienced significantly more frequently in the atomoxetine group, compared with the methylphenidate group, included anorexia (37.2% vs. 25.3%; p = 0.024), nausea (20.1% vs. 10.2%; p = 0.014), somnolence (26.2% vs. 3.6%; p &lt;0.001), dizziness (15.2% vs. 7.2%; p = 0.024) and vomiting (11.6% vs. 3.6%; p = 0.007), most of which were of mild or moderate severity. Atomoxetine-treated patients experienced a small but significantly greater mean weight loss from baseline to end point than methylphenidate-treated patients (\u22121.2 kg vs. \u22120.4 kg; p &lt;0.001).<\/jats:p>\n                  <jats:p>Conclusions: This study suggests that atomoxetine is non-inferior to methylphenidate in the improvement of ADHD symptoms in paediatric outpatients. Although both of the drugs were well tolerated, atomoxetine was associated with a higher incidence of TEAEs than methylphenidate.<\/jats:p>","DOI":"10.1080\/00048670601057767","type":"journal-article","created":{"date-parts":[[2007,3,30]],"date-time":"2007-03-30T00:29:12Z","timestamp":1175214552000},"page":"222-230","source":"Crossref","is-referenced-by-count":71,"title":["Atomoxetine\n                    <i>versus<\/i>\n                    Methylphenidate in Paediatric Outpatients with Attention Deficit Hyperactivity Disorder: A Randomized, Double-Blind Comparison Trial"],"prefix":"10.1177","volume":"41","author":[{"given":"Yufeng","family":"Wang","sequence":"first","affiliation":[{"name":"Institute of Mental Health, Beijing Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zheng","sequence":"additional","affiliation":[{"name":"Beijing An Ding Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasong","family":"Du","sequence":"additional","affiliation":[{"name":"Shanghai Mental Health Center, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong H.","family":"Song","sequence":"additional","affiliation":[{"name":"Younsei University Youngdong Severance Hospital, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yee-Jin","family":"Shin","sequence":"additional","affiliation":[{"name":"Younsei University Youngdong Severance Hospital, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo C.","family":"Cho","sequence":"additional","affiliation":[{"name":"Seoul National University Hospital, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bung N.","family":"Kim","sequence":"additional","affiliation":[{"name":"Seoul National University Hospital, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong H.","family":"Ahn","sequence":"additional","affiliation":[{"name":"Hanyang University Hospital, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria E.","family":"Marquez-Caraveo","sequence":"additional","affiliation":[{"name":"Child Psychiatric Hospital \u2018Dr Juan N. Navarro\u2019, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Gao","sequence":"additional","affiliation":[{"name":"Neuroscience Products, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, 46285, US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Williams","sequence":"additional","affiliation":[{"name":"Neuroscience Products, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, 46285, US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise R.","family":"Levine","sequence":"additional","affiliation":[{"name":"Neuroscience Products, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, 46285, US"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2007,3,1]]},"reference":[{"key":"bibr1-00048670601057767","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2001.tb05773.x"},{"key":"bibr2-00048670601057767","doi-asserted-by":"publisher","DOI":"10.1001\/jama.279.14.1100"},{"key":"bibr3-00048670601057767","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(99)00192-4"},{"key":"bibr4-00048670601057767","volume-title":"Diagnostic and statistical manual of mental disorders4th edn","author":"American Psychiatric Association","year":"2000"},{"key":"bibr5-00048670601057767","doi-asserted-by":"publisher","DOI":"10.1037\/0021-843X.111.2.279"},{"key":"bibr6-00048670601057767","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.148.5.564"},{"key":"bibr7-00048670601057767","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199105000-00005"},{"key":"bibr8-00048670601057767","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.56.12.1073"},{"key":"bibr9-00048670601057767","first-page":"422","volume":"210","author":"Ferris RM","year":"1979","journal-title":"J Pharmacol Exp Ther"},{"key":"bibr10-00048670601057767","doi-asserted-by":"publisher","DOI":"10.1002\/jclp.20122"},{"key":"bibr11-00048670601057767","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.1994.tb03740.x"},{"key":"bibr12-00048670601057767","doi-asserted-by":"publisher","DOI":"10.1016\/S1056-4993(18)30455-3"},{"key":"bibr13-00048670601057767","doi-asserted-by":"publisher","DOI":"10.1016\/S0893-133X(02)00346-9"},{"key":"bibr14-00048670601057767","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199604000-00008"},{"key":"bibr15-00048670601057767","doi-asserted-by":"crossref","first-page":"16","DOI":"10.4088\/JCP.v63n1209","volume":"63","author":"Spencer TJ","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"bibr16-00048670601057767","first-page":"14","volume":"58","author":"Popper CW","year":"1997","journal-title":"J Clin Psychiatry"},{"key":"bibr17-00048670601057767","doi-asserted-by":"publisher","DOI":"10.1542\/peds.114.1.e1"},{"key":"bibr18-00048670601057767","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(02)00053-4"},{"key":"bibr19-00048670601057767","doi-asserted-by":"publisher","DOI":"10.1542\/peds.108.5.e83"},{"key":"bibr20-00048670601057767","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.159.11.1896"},{"key":"bibr21-00048670601057767","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v63n1209"},{"key":"bibr22-00048670601057767","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(02)01671-2"},{"key":"bibr23-00048670601057767","doi-asserted-by":"publisher","DOI":"10.1097\/01.chi.0000163280.47221.c9"},{"issue":"10","key":"bibr24-00048670601057767","first-page":"11S","volume":"97","author":"Starr HL","year":"2005","journal-title":"J Nat Med Assoc"},{"key":"bibr25-00048670601057767","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-200207000-00008"},{"key":"bibr26-00048670601057767","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199707000-00021"},{"key":"bibr27-00048670601057767","doi-asserted-by":"crossref","unstructured":"27. DuPaul GJ, Power TJ, Anastopoulos AD, ADHD rating scale-IV checklists, norms, and clinical interpretation. The Guilford Press, New York 1998; 28\u201342.","DOI":"10.1037\/t00680-000"},{"key":"bibr28-00048670601057767","doi-asserted-by":"crossref","unstructured":"28. Guy W. ECDEU assessment manual for psychopharmacology, revised. National Institute of Mental Health, Psychopharmacology Research Branch, Rockville, MD 1976; 217\u2013222.","DOI":"10.1037\/e591322011-001"},{"key":"bibr29-00048670601057767","volume-title":"Conners\u2019 rating scales-revised, technical manual","author":"Conners CK","year":"1997"},{"key":"bibr30-00048670601057767","doi-asserted-by":"publisher","DOI":"10.1542\/peds.110.6.e75"},{"key":"bibr31-00048670601057767","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.155.5.693"},{"key":"bibr32-00048670601057767","doi-asserted-by":"publisher","DOI":"10.1089\/104454601750284072"},{"key":"bibr33-00048670601057767","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1542\/peds.98.4.748","volume":"98","author":"Stein MA","year":"1996","journal-title":"Pediatrics"},{"key":"bibr34-00048670601057767","doi-asserted-by":"publisher","DOI":"10.1542\/peds.107.6.e105"},{"key":"bibr35-00048670601057767","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2004-0624"},{"key":"bibr36-00048670601057767","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-977X(02)80706-4"},{"key":"bibr37-00048670601057767","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-200102000-00012"},{"key":"bibr38-00048670601057767","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199610000-00017"}],"container-title":["Australian &amp; New Zealand Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1080\/00048670601057767","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1080\/00048670601057767","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1080\/00048670601057767","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:51:06Z","timestamp":1777373466000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1080\/00048670601057767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,3]]}},"alternative-id":["10.1080\/00048670601057767"],"URL":"https:\/\/doi.org\/10.1080\/00048670601057767","relation":{},"ISSN":["0004-8674","1440-1614"],"issn-type":[{"value":"0004-8674","type":"print"},{"value":"1440-1614","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,3]]}}}